Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
B-ALL refractory to treatment or in the second or subsequent relapse (hematological OR molecular), OR
B-NHL refractory to treatment or in first relapse ineligible for autologous stem cell transplantation (ASCT) or in second to fourth relapse, OR
B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell transplantation (HCT).
CD19 expression on malignant cells confirmed by flow cytometry or by immunohistochemistry.
Known hypersensitivity to any component of the Investigational Medicinal Product (IMP).
Autologous or allogeneic HCT in 3 months prior to IMP administration.
Severe, uncontrolled active infection.
Life expectancy < 6 weeks.
Institute of Hematology and Blood Transfusion, Czech Republic
Lead sponsor